Smith & Nephew (LSE:SN, NYSE: $SNN) launches digital platform to engage patients and track outcomes following orthopaedic surgery
March 12, 2018 (Investorideas.com Newswire) Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces the launch of a new digital platform that enables orthopaedic surgeons, for the first time, to remotely track their patients' real-time healing progress and satisfaction without requiring a clinical visit.
In partnership with Wellframe Inc., a mobile-enabled care management solution provider, Smith & Nephew utilises HealthMeasures's Patient-Reported Outcomes Measurement Information System (PROMIS)® Computer-Adaptive Tests (CATs) to collect data from patients by measuring their recovery at regular time points. The Wellframe platform includes a care team dashboard and an interactive, patient mobile application, available on Apple and Android devices. Key components of the application include a personalised, daily checklist with education and reminders to patients to engage in behaviours required to aid their surgery preparation and rehabilitation, as well as messaging between surgical teams and patients.
Collecting Patient-Reported Outcomes is important to assess the effectiveness of clinical procedures. More than 25% of NHS post-operative paper PROs are not completed2, something which prevents the accurate assessment of outcomes. Often time-consuming and inefficient, traditional PROs require patients to answer long surveys of up to 40 or more questions on their well-being and healing at each post-operative check-up visit.
PROMIS® CAT can be significantly quicker than traditional paper-based PRO methods, intuitively guiding patients through an average of five to seven questions that are calibrated to reflect previous answers. A respondent's current state of health and satisfaction is recorded quickly and precisely with surgeons able to track their patients progress interactively on a more regular basis rather than relying on unnecessary clinical visits.
Smith & Nephew has launched research studies in the UK and US at select hospitals. One of the clinical investigators, Professor Iain McNamara, Norfolk and Norwich University Hospitals NHS Foundation Trust in the UK, said:
"Traditional PRO collection is time-consuming and often burdensome for both patients and HCPs. Using mobile technology is a significant improvement over standard care, providing the patient with an easy-to-use tool to report their progress and enabling surgeons to track patient recovery closely. Moreover, the PRO data collection is seamless, and enables us to also evaluate our hospital's performance."
"The effectiveness of an orthopaedic procedure is dependent on the skill of the surgeon, the product used and the commitment of the patient to follow their recovery programme. Our innovative platform has the potential to revolutionise the recovery process for each patient and provide invaluable data to inform future innovation and clinical practice," said Andy Weymann, Chief Medical Officer, Smith & Nephew.
"Smith & Nephew has a bold vision to advance PRO capture and enhance patient outcomes, by providing additional value to clinicians and patients. We're thrilled to have the opportunity to support this effort," said Jacob Sattelmair, CEO, Wellframe.
The Smith & Nephew PROMIS® CAT platform utilises technology from Wellframe Inc., the makers of the mobile patient engagement and care management software platform.
1 Ayers, D. C., Zheng, H., & Franklin, P. D. (2013). Integrating Patient-reported Outcomes Into Orthopaedic Clinical Practice: Proof of Concept From FORCE-TJR. Clinical Orthopaedics and Related Research, 471(11), 3419–3425.
2 Information from Participation and Coverage. www.digital.nhs.uk/catalogue/PUB30036. Accessed 21 February 2018.
Smith & Nephew
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
About Wellframe Inc.
Wellframe, based in Boston, Massachusetts, partners with leading health plans and providers to transform care management and patient engagement. Our mobile-enabled care management program optimally extends existing care management systems and resources to provide patients with ongoing guidance and support, when and where they need it. Wellframe's data driven approach delivers proven results including improved patient experience, reduced medical spend and increased efficiency.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.